Matches in Nanopublications for { ?s ?p ?o <http://rdf.disgenet.org/nanopublications.trig#NP287259.RAOX85NXbS9ksLmcav-UVoUhZ9g-iRG9ZjchRF5w5cGdE130_provenance>. }
Showing items 1 to 9 of
9
with 100 items per page.
- source_evidence_literature type ECO_0000212 NP287259.RAOX85NXbS9ksLmcav-UVoUhZ9g-iRG9ZjchRF5w5cGdE130_provenance.
- source_evidence_literature label "DisGeNET evidence - LITERATURE" NP287259.RAOX85NXbS9ksLmcav-UVoUhZ9g-iRG9ZjchRF5w5cGdE130_provenance.
- source_evidence_literature comment "Gene-disease associations inferred from text-mining the literature." NP287259.RAOX85NXbS9ksLmcav-UVoUhZ9g-iRG9ZjchRF5w5cGdE130_provenance.
- NP287259.RAOX85NXbS9ksLmcav-UVoUhZ9g-iRG9ZjchRF5w5cGdE130_assertion description "[These data indicate that quantity and lytic efficiency of CD16(+) lymphocytes are major factors for ADCC induction by trastuzumab, and confirm that breast cancer responses to short-term trastuzumab monotherapy may depend on involvement of the ADCC mechanism.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP287259.RAOX85NXbS9ksLmcav-UVoUhZ9g-iRG9ZjchRF5w5cGdE130_provenance.
- NP287259.RAOX85NXbS9ksLmcav-UVoUhZ9g-iRG9ZjchRF5w5cGdE130_assertion evidence source_evidence_literature NP287259.RAOX85NXbS9ksLmcav-UVoUhZ9g-iRG9ZjchRF5w5cGdE130_provenance.
- NP287259.RAOX85NXbS9ksLmcav-UVoUhZ9g-iRG9ZjchRF5w5cGdE130_assertion SIO_000772 18089830 NP287259.RAOX85NXbS9ksLmcav-UVoUhZ9g-iRG9ZjchRF5w5cGdE130_provenance.
- NP287259.RAOX85NXbS9ksLmcav-UVoUhZ9g-iRG9ZjchRF5w5cGdE130_assertion wasDerivedFrom befree-20140225 NP287259.RAOX85NXbS9ksLmcav-UVoUhZ9g-iRG9ZjchRF5w5cGdE130_provenance.
- NP287259.RAOX85NXbS9ksLmcav-UVoUhZ9g-iRG9ZjchRF5w5cGdE130_assertion wasGeneratedBy ECO_0000203 NP287259.RAOX85NXbS9ksLmcav-UVoUhZ9g-iRG9ZjchRF5w5cGdE130_provenance.
- befree-20140225 importedOn "2014-02-25" NP287259.RAOX85NXbS9ksLmcav-UVoUhZ9g-iRG9ZjchRF5w5cGdE130_provenance.